Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | retinoic acid receptor, gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | nuclear hormone receptor | Get druggable targets OG5_131607 | All targets in OG5_131607 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_131607 | All targets in OG5_131607 |
Loa Loa (eye worm) | nuclear receptor nhr-7B | Get druggable targets OG5_131607 | All targets in OG5_131607 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | Get druggable targets OG5_131607 | All targets in OG5_131607 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.0262 | 0.7376 | 0.7376 |
Trichomonas vaginalis | cdc25c, putative | 0.0057 | 0.1313 | 0.5 |
Onchocerca volvulus | 0.0057 | 0.1313 | 0.1736 | |
Trichomonas vaginalis | m-phase inducer phosphatase, putative | 0.0057 | 0.1313 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.1183 | 0.1183 |
Loa Loa (eye worm) | hypothetical protein | 0.0057 | 0.1313 | 0.1313 |
Onchocerca volvulus | 0.0057 | 0.1313 | 0.1736 | |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.0057 | 0.1313 | 0.5 |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.0057 | 0.1313 | 0.5 |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.0057 | 0.1313 | 0.5 |
Echinococcus multilocularis | tyrosine protein phosphatase non receptor type | 0.0351 | 1 | 1 |
Brugia malayi | nuclear hormone receptor | 0.0262 | 0.7376 | 0.7376 |
Onchocerca volvulus | 0.0057 | 0.1313 | 0.1736 | |
Schistosoma mansoni | protein tyrosine phosphatase non-receptor type nt1 | 0.0351 | 1 | 1 |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.0057 | 0.1313 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0256 | 0.7206 | 0.7206 |
Echinococcus granulosus | m phase inducer phosphatasecdc25 | 0.0057 | 0.1313 | 0.1313 |
Trichomonas vaginalis | cdc25b, putative | 0.0057 | 0.1313 | 0.5 |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.0057 | 0.1313 | 0.5 |
Schistosoma mansoni | m-phase inducer phosphatase(cdc25) | 0.0057 | 0.1313 | 0.1313 |
Trichomonas vaginalis | cdc25b, putative | 0.0057 | 0.1313 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0057 | 0.1313 | 0.1313 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0269 | 0.7566 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.1183 | 0.1183 |
Trichomonas vaginalis | m-phase inducer phosphatase, putative | 0.0057 | 0.1313 | 0.5 |
Onchocerca volvulus | 0.0057 | 0.1313 | 0.1736 | |
Echinococcus granulosus | tyrosine protein phosphatase non receptor type | 0.0351 | 1 | 1 |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.0057 | 0.1313 | 0.5 |
Loa Loa (eye worm) | protein-tyrosine phosphatase | 0.0351 | 1 | 1 |
Brugia malayi | Rhodanese-like domain containing protein | 0.0057 | 0.1313 | 0.1313 |
Echinococcus multilocularis | m phase inducer phosphatase(cdc25) | 0.0057 | 0.1313 | 0.1313 |
Brugia malayi | Rhodanese-like domain containing protein | 0.0057 | 0.1313 | 0.1313 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 710 nM | Inhibition of [3H]-RA to binding Retinoic acid receptor RAR gamma | ChEMBL. | No reference |
Ki (binding) | = 710 nM | Inhibition of [3H]-RA to binding Retinoic acid receptor RAR gamma | ChEMBL. | No reference |
Tumor (functional) | = 0.92 number | Antitumor activity against DMBA-induced mammary tumors in rats | ChEMBL. | No reference |
Tumor incidence (functional) | = 58 % | Antitumor activity against DMBA-induced mammary tumors in rats | ChEMBL. | No reference |
Tumor latency (functional) | = 64 day | Antitumor activity against DMBA-induced mammary tumors in rats | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.